Invasight, a Zurich-based clinical biotech company, is making waves in the fields of Biopharma, Biotechnology, and Health Care. Established in 2019, the company has been a pioneer in cell invasion research, which is a critical area for advancing cancer treatment and other medical innovations.
Their most recent financing, a Fr.4.50M Seed Round investment secured on 07 June 2022, highlights a robust backing from seasoned investors. Key participants included Verve Ventures, Occident, Wille AG, JFG Life Sciences Foundation, Zürcher Kantonal Bank, AVANTECA Partners, and HTGF | High-Tech Gruenderfonds.
With an increasingly essential focus on cell invasion, Invasight is strategically positioned to capitalize on the growing market demand for innovative biotechnological solutions. Investors might find Invasight appealing due to their cutting-edge research approach and strong foundational support from reputed financial partners.
